Showing 20 of 37 recruiting trials for “IgA Nephropathy”
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
PS-002 for the Treatment of IgA Nephropathy in Adults
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
🏥 Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.📍 1 site📅 Started Sep 2025View details ↗
Nefecon and Ambrisentan in IgA Nephropathy
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
Atacicept in Multiple Glomerular Diseases
Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)
RecruitingNCT06926244 ↗
RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
Monthly Dosing of Atacicept in IgAN
Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
RecruitingNCT06952426 ↗
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Efficacy and Safety of Telitacicept in IgAN
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →